What is ENLV (ENLV) stock price today?

ENLV (ENLV) is currently trading at $1.25, down 2.34% today.

What is ENLV P/E ratio?

ENLV's P/E ratio is 0.03. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ENLV return on equity (ROE)?

ENLV's return on equity (ROE) is 63.88%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is ENLV's market cap?

ENLV has a market capitalization of $21.04M.

NASDAQ · Biotechnology

ENLV (ENLV) Stock

$1.25 -2.34% NASDAQ: ENLV Healthcare

Valuation

Metric	Value
Price	$1.25
Market Cap	$21.04M
P/E Ratio	0.03
P/B Ratio	0.01
P/S Ratio	0.00
EPS (TTM)	$25.48
52-Week High	$7.40
52-Week Low	$0.44
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	63.88%
ROA	53.12%
ROCE	-0.78%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	193.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-19.0M	$-26.0M	$-29.0M	$-16.0M	$-15.0M
Net Profit	$-14.0M	$-31.0M	$-29.0M	$-15.0M	$1.2B
EPS	$-0.54	$-2.31	$-1.56	$-0.73	$25.48
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$95.0M	$68.0M	$37.0M	$28.0M	$2.3B
Total Liabilities	$10.0M	$11.0M	$7.0M	$4.0M	$392.0M
Cash	$11.0M	$48.0M	$1.0M	$3.0M	$2.0M
Borrowings	$1.0M	$5.0M	$1.0M	$1.0M	$1.0M

Latest News

Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis MT Newswires · Jun 15, 2026 Enlivex advances Allocetra while expanding into prediction markets Proactive · May 11, 2026 Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress GlobeNewswire · Apr 23, 2026 H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook Insider Monkey · Apr 21, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-18.0M	$-24.0M	$-24.0M	$-13.0M	$-10.0M
Investing Cash Flow	$-40.0M	$54.0M	$-26.0M	$9.0M	$-1.0M
Financing Cash Flow	$8.0M	$0	$0	$0	$0
Net Cash Flow	$5.0M	$39.0M	$-49.0M	$3.0M	$-1.0M
Free Cash Flow	$-19.0M	$-32.0M	$-24.0M	$-13.0M	$-10.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-64.87%
Quick Ratio	193.24
Interest Coverage	—
Return 1Y	-67.59%
Return 3Y	-83.25%
Return 5Y	-94.66%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLGN	$0.34	-7.86%	-0.48	$4.45M	0.00%
CVKD	$1.33	-11.92%	-0.78	$4.74M	0.00%
GDTC	$0.88	-3.17%	-4.00	$10.41M	0.00%
LSTA	$1.57	+0.00%	-1.66	$14.30M	0.00%
MTVA	$1.82	+5.81%	-0.45	$4.01M	0.00%

About ENLV

ENLV is led by CEO Oren Hershkovitz, employs 71 people, headquartered in IL, publicly traded since 2014.

ENLV stock trades at $1.25 with a market capitalization of $21.04M. The stock is valued at a price-to-earnings (P/E) ratio of 0.03, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.44 and $7.40, and currently trades 83.1% below its 52-week high.

On profitability, ENLV generates a return on equity (ROE) of 63.88% — well above the market average, a sign of a high-quality business, return on capital employed of -0.78%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides